Across TCGA pan-cancer cohorts, DEFB126 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated DEFB126 data layer compared with 20 for mass-spec protein.
The strongest signal is observed in small cell lung cancer (SCLC), where higher DEFB126 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DEFB126 expression acts as an unfavorable survival marker.
SCLC are the cancer types where DEFB126 Mutation most reproducibly stratifies survival.